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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-21-

STATE OF MAINE
KENNEBEC, SS.

STATE OF MAINE,
Plaintiff
V.

BOSTON SCIENTIFIC CORPORATION:
Defendant

)
)
)
)
)
)
)
)
)
)

COMPLAINT
(Injunctive Relief Requested)

NOW COMES the Plaintiff, the State of Maine, by and through its Attorney General, Aaron
M, Frey who, pursuant to 5 M.R.S.A. § 209, brings this action against Defendant Boston Scientific
Corporation for violating 5 M.R.S.A. § 207 o f the Unfair Trade Practices Act (5 M.R.S.A. §§ 205-A
through 214, the “UTPA”), and states as follows:
The Parties
1.

Plaintiff, the State of Maine, through its Attorney General, is charged with,

among other things, enforcing and seeking redress for violations o f Maine's consumer
protection laws, including the UTPA.
2.

Defendant Boston Scientific Corporation (“Boston Scientific") is a Delaware

corporation that is headquartered at 300 Boston Scientific Way, Marlborough, MA 017521234.
3.

At all times relevant hereto, Defendant Boston Scientific transacted business in

the State o f Maine and nationwide by marketing, promoting, advertising, offering for sale,

selling, and distributing transvaginal surgical mesh devices, and that business is subject to
Maine’s UTPA.
Jurisdiction and Venue
4.

This Court has jurisdiction over the Defendant pursuant to 14 M.R.S.A. § 704-

A(2)(4) and 5 M.R.S.A. § 209 because Defendant Boston Scientific has transacted business within
the State of Maine at all times relevant to the Complaint.
5.

Venue is proper in Kennebec County pursuant to 5 M.R.S.A. § 209 because

Defendant Boston Scientific has carried on regular business in the State o f Maine.
Background
6.

“Surgical Mesh,” as used in this Complaint, is a medical device that contains

synthetic polypropylene mesh intended to be implanted in the pelvic floor to treat stress urinary
incontinence (“SUI”) and/or pelvic organ prolapse (“POP”) manufactured and sold by Boston
Scientific in the United States.
7.

SUI and POP are common conditions that pose lifestyle limitations but are not life-

threatening.
8.

SUI is a leakage of urine during episodes o f physical activity that increase

abdominal pressure, such as coughing, sneezing, laughing, or exercising. SUI can happen when
pelvic tissues and muscles supporting the bladder and urethra become weak and allow the neck
of the bladder to descend during bursts o f physical activity, which can prevent the urethra from
working properly to control the flow o f urine, SUI can also result when the sphincter muscle that
controls the urethra weakens and is not able to stop the flow o f urine under normal circumstances
and with an increase in abdominal pressure.

9.

POP happens when the tissue and muscles of the pelvic floor fail to support the

pelvic organs resulting in the drop of the pelvic organs from their normal position. Not all
women with POP have symptoms, while some experience pelvic discomfort or pain, pressure,
and other symptoms.
10.

In addition to addressing symptoms, such as wearing absorbent pads, there are a

variety of non-surgical and surgical treatment options to address SUI and POP. Non-surgical
options for SUI include pelvic floor exercises, pessaries, transurethral bulking agents, and
behavior modifications. Surgery for SUI can be done through the vagina or abdomen to provide
support for the urethra or bladder neck with either stitches alone, tissue removed from other parts
of the body, tissue from another person, or with material such as surgical mesh, which is
permanently implanted. Non-surgical options for POP include pelvic floor exercises and
pessaries. Surgery for POP can he done through the vagina or abdomen using stitches alone or
with the addition o f surgical mesh.
11.

Boston Scientific marketed and sold Surgical Mesh devices to be implanted

transvaginally for the treatment of POP for approximately 10 years or more. Boston Scientific
ceased the sale of Surgical Mesh devices to be implanted transvaginally for the treatment of POP
after the Food and Drug Administration (“FDA”) ordered manufacturers o f such products to
cease the sale and distribution of the products in April 2019.
12.

By 2003 Boston Scientific began marketing and selling Surgical Mesh devices to

he implanted transvaginally for the treatment of SUI, and it continues to market and sell Surgical
Mesh devices to be implanted transvaginally for the treatment of SUL
13.

The FDA applies different levels of scrutiny to medical devices before approving

or clearing them for sale.

14.

The most rigorous level of scrutiny is the premarket approval (“PMA”) process,

which requires a manufacturer to submit detailed information to the FDA regarding the safety
and effectiveness of its device.
15.

The 510(k) review is a much less rigorous process than the PMA review process.

Under this process, a manufacturer is exempt from the PMA process and instead provides
premarket notification to the FDA that a medical device is “substantially equivalent” to a legally
marketed device. While PMA approval results in a finding of safety and effectiveness based on
the manufacturer’s submission and any other information before the FDA, 510(k) clearance
occurs after a finding of substantial equivalence to a legally marketed device. The 510(k)
process is focused on equivalence, not safety.
16.

Boston Scientific’s SUI and POP Surgical Mesh devices entered the market under

the 510(k) review process. Boston Scientific marketed and sold Surgical Mesh devices without
adequate testing.
Boston Scientific’s Course of Conduct
17.

In marketing Surgical Mesh devices, Boston Scientific misrepresented and failed

to disclose the full range o f risks and complications associated with the devices, including
misrepresenting the risks of Surgical Mesh as compared with the risks of other surgeries or
surgically implantable materials.
18.

Boston Scientific misrepresented the safety of its Surgical Mesh by

misrepresenting the risks of its Surgical Mesh, thereby making false and/or misleading
representations about its risks.
19.

Boston Scientific also made material omissions when it failed to disclose the risks

of its Surgical Mesh.

20.

Boston Scientific misrepresented and/or failed to adequately disclose serious risks

and complications of one or more o f its transvaginally-placed Surgical Mesh products, including
the following:
a. Heightened risk of infection;
b. Rigid scar plate formation;
c. Mesh shrinkage;
d. Voiding dysfunction;
e. De novo incontinence;
f.

Urinary tract infection;

g. Risk of delayed occurrence of complications; and
h. Defecatory dysfunction.
21.

Throughout its marketing of Surgical Mesh, Boston Scientific continually failed to

disclose risks and complications it knew to be inherent in the devices and/or misrepresented those
inherent risks and complications as caused by physician error, surgical technique, or perioperative
risks.
22.

In 2008, the FDA issued a Public Health Notification to inform doctors and patients

about serious complications associated with surgical mesh placed through the vagina to treat
POP or SUI. In 2011, the FDA issued a Safety Communication to inform doctors and patients
that serious complications associated with surgical mesh for the transvaginal repair of POP are
not rare; that a systematic review of published literature showed that transvaginal POP repair
with mesh does not improve symptomatic results or quality of life over traditional non-mesh
repair; and that mesh used in transvaginal POP repair introduces risks not present in traditional
non-mesh surgery for POP repair.

23.

In 2012, the FDA ordered post-market surveillance studies by manufacturers of

surgical mesh to address specific safety and effectiveness concerns related to surgical mesh used
for the transvaginal repair of POP. In 2016, the FDA issued final orders to reclassify
transvaginal POP devices as Class III (high risk) devices and to require manufacturers to submit
a PMA application to support the safety and effectiveness of surgical mesh for the transvaginal
repair o f POP in order to continue marketing the devices.
24.

In April 2019, the FDA ordered manufacturers of surgical mesh devices intended

for transvaginal repair of POP to cease the sale and distribution of those products in the United
States. The FDA determined that Boston Scientific had not demonstrated a reasonable assurance
of safety and effectiveness for these devices under the PMA standard. On or around April 16,
2019, Boston Scientific announced it would stop global sales of its transvaginal mesh products
indicated for POP.
Violation of Section 207 of the UTPA
25.

Plaintiff realleges and incorporates by reference each and every allegation

contained in the preceding paragraphs 1 through 24 as if they were set forth fiilly herein.
26.

In the course of marketing, promoting, selling, and distributing Surgical Mesh

products, Boston Scientific made false statements about, misrepresented, and/or made other
representations about the risks of Surgical Mesh products that had the effect, capacity, or
tendency, of deceiving or misleading consumers. Such false statements and misrepresentations
constitute unfair or deceptive trade practices that are prohibited by § 207 o f the UTPA.
27.

In the course of marketing, promoting, selling, and distributing Surgical Mesh

products, Boston Scientific has made representations concerning the characteristics, uses,
benefits, and/or qualities of Surgical Mesh products that they did not have. Such false statements

and misrepresentations constitute unfair or deceptive trade practices that are prohibited by § 207
oftheU TPA .
28.

Defendant Boston Scientific made material omissions concerning the risks and

complications associated with Surgical Mesh products, and those material omissions had the
effect, capacity, or tendency of deceiving consumers. Such omissions constitute unfair or
deceptive trade practices that are prohibited by § 207 of the UTPA.
29.

The acts or practices described herein occurred in trade or commerce as defined

in § 206(3)(A) of the UTPA.
30.

These acts or practices affected the public interest because they impacted

numerous Maine consumers.
Request for Relief
WHEREFORE, Plaintiff respectfully requests that this Honorable Court enter an Order
that;
1.

Adjudges and decrees that Defendant has engaged in the acts or practices

complained of herein, and that such constitute unfair and/or deceptive acts or practices in
violation o f § 207 o f the UTPA;
2.

Pursuant to § 209 of the UTPA, issues a permanent injunction prohibiting

Defendant, its agents, servants, employees, and all other persons and entities, corporate or
otherwise, in active concert or participation with any o f them, from engaging in unfair or
deceptive trade practices in the marketing, promoting, selling and distributing of Defendant’s
Surgical Mesh devices;
3.

Pursuant to § 209 of the UTPA, orders Defendant to pay civil penalties in the

amount o f up to $10,000 for each and every intentional violation o f § 207 o f the UTPA;

4.

Order Defendant to pay all costs and reasonable attorney’s fees for the

prosecution and investigation of this action, pursuant to § 209 of the UTPA;
5.

Order Defendant to provide monetary restitution to consumers impacted by the

acts and practices detailed above, pursuant to § 209 of the UTPA;
6.

Order such other and further relief as the Court may deem just and proper.

Dated: March 23,2021

Respectfully submitted,
AARON M. FREY
ATTORNEY GENERAL

Carolyn A. Sjflsby, ME Bar No. 3
Carolyn.silsby@maine.gov
Linda J. Conti, ME Bar No. 3638
Linda.conti@maine.gov
Assistant Attorneys General
Office o f the Attorney General
6 State House Station
Augusta, ME 04333-0006
(207) 626-8800

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-21-

STATE OF MAINE
KENNEBEC, SS.

STATE OF MAINE,
Plaintiff
v.

CONSENT JUDGMENT

BOSTON SCIENTIFIC CORPORATION,
Defendant

Plaintiff, the State o f Maine (the “State” or “Plaintiff') has filed a Complaint for a
permanent injunction and other relief in this matter pursuant to 5 M.R.S.A. § 209 o f the Maine
Unfair Trade Practices Act, 5 M.R.S.A, §§ 205-A through 214 (the “UTPA”), alleging that
Defendant Boston Scientific Corporation (“BSC” or “Defendant”) committed violations o f the
UTPA. Plaintiff, by its counsel, and Defendant, by its counsel, have agreed to the entry o f this
Consent Judgment (“Judgment”) by the Court without trial or adjudication o f any issue of fact or
law, and without finding or admission o f wrongdoing or liability o f any kind.
IT IS HEREBY ORDERED THAT:
I.
1.1

FINDINGS

This Court has jurisdiction over the subject matter of this lawsuit and over all

Parties.
1.2

The terms of this Judgment shall be governed by the laws o f the State of Maine.

1.3

The State o f Maine contends that entry o f this Judgment is in the public interest.

The Judgment reflects a negotiated agreement among the Parties.

US.126846896.01

1.4

BSC is willing to enter into this Judgment regarding the Covered Conduct to resolve

the Attorney General’s concerns under the State Consumer Protection Laws as to the matters
addressed in this Judgment and thereby avoid significant expense, inconvenience, and uncertainty.
1.5

The Parties have agreed to resolve the issues raised by the Covered Conduct by

entering into this Judgment.1
1.6

BSC is entering into this Judgment solely for the purpose o f settlement, and nothing

contained herein may be taken as or construed to be an admission or concession o f any violation
of law, rule, or regulation, or o f any other matter o f fact or law, or of any liability or wrongdoing,
all of which BSC expressly denies. BSC does not admit any violation o f the State Consumer
Protection Laws set forth in Footnote 4, and does not admit any wrongdoing that was, or could
have been, alleged by any Attorney General before the date o f the Judgment under those laws. No
part of this Judgment, including its statements and commitments, shall constitute evidence o f any
liability, fault, or wrongdoing by BSC. This document and its contents are not intended for use by
any third party for any purpose, including submission to any court for any purpose. This Judgment
shall not be construed or used as a waiver or limitation o f any defense otherwise available to BSC
in any other action, or of B SC ’s right to defend itself from, or to make any arguments in, any
private individual or class action claims or suits, or any other governmental or regulatory
investigations or suits, relating to the subject matter or terms o f this Judgment. This Judgment is
made without trial or adjudication of any issue o f fact or law or finding o f liability o f any kind.
Notwithstanding the foregoing, a State may file an action to enforce the terms o f this Judgment.
1.7

It is the intent o f the Parties that this Judgment not be admissible in other cases or

binding on BSC in any respect other than in connection with the enforcement o f this Judgment.

1 This Consent Judgment is entered into pursuant to and subject to the State Consumer Protection laws cited in
Footnote 4.
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1.8

No part of this Judgment shall create a private cause o f action or confer any right

to any third party for violation of any federal or state statute, except that a State may file an action
to enforce the terms o f this Judgment.
1.9

This Judgment (or any portion thereof) shall in no way be construed to prohibit

BSC from making representations with respect to any o f BSC’s products in Labeling that are
required under Federal law, regulations, and policies or guidance having the force o f law.
1.10

Nothing in this Judgment shall require BSC to:

(a)

Take any action that is prohibited by the Federal Food, Drug and Cosmetic Act, 21
U.S.C, § 301 etseq. (“FDCA”) or any regulation promulgated thereunder or by the
FDA; or

(b)

Fail to take any action that is required by the FDA, or by the FDCA or any
regulation promulgated thereunder.
II.

DEFINITIONS

The following definitions shall be used in construing the Judgment:
2.1

“Covered Conduct” means B SC ’s marketing and promotional practices and

dissemination o f information to Health Care Providers or consumers regarding BSC Surgical Mesh
products through the Effective Date o f the Judgment.
2.2

“Effective Date” means the date on which a copy o f the Judgment, duly executed

by BSC and by the Signatory Attorney General, is approved by, and becomes a Judgment o f the
Court.
2.3

“Health Care Provider” or “HCP” means any physician who in the course o f his or

her practice may prescribe or implant BSC Surgical Mesh.
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2.4

“BSC” or “Defendant” means Boston Scientific Corporation, and all o f its officers,

directors, employees, representatives, agents, affiliates, parents, subsidiaries, operating companies,
assigns, and successors.
2.5

“Labeling” as used in this Judgment shall carry the same definition as that contained

in the Federal FDCA, specifically “all labels and other written, printed, or graphic matter (1) upon
any article or any o f its containers or wrappers, or (2) accompanying such article” and as
interpreted by the courts and through FDA policy and guidance to encompass, among other things,
“posters, tags, pamphlets, circulars, booklets, brochures, instruction books, [and] direction sheets.”
2.6

“Marketing Materials” means any written or electronic material, or written or

verbal statements either publicly disseminated or made by or on behalf o f BSC for the purpose of
public dissemination to induce a sale or purchase in the United States in the course o f marketing,
promoting, or informing HCPs, nurses, physician’s assistants, other medical professionals, and
consumers about BSC Surgical Mesh, including: Directions for Use (“DFUs”), pamphlets,
brochures, Frequently Asked Questions (“FAQs”), sales representative training materials
containing material or statements intended to be publicly disseminated, HCP training materials,
communications with HCPs, presentations (including poster presentations and abstract
presentations), seminars, videos, advertisements in any form o f media, and websites hosted or
controlled by BSC.
2.7

“Multistate Executive Committee” means the Attorneys General and their staffs

representing California, Florida, Indiana, Maryland, Ohio, South Carolina, Texas, and
Washington.
2.8

“Multistate Working Group” means the Attorneys General and their staffs

representing Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware,

4

District o f Columbia, Florida, Georgia, Hawaii2, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky,
Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,
Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, N ew York, North
Carolina, N orth Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South
Dakota, Tennessee, Texas, Utah3, Vermont, Virginia, Washington, and Wisconsin,
2.9

“Parties” means BSC as defined in Section 2.4 and the Signatory Attorney General,

2.10

“Significant Complications” means complications of BSC Surgical Mesh,

including complications discovered subsequent to the Effective Date, which:
a.

Are required to be included in product labeling or advertisements pursuant to FDA
regulations;

b.

Can result in a “serious injury” as defined by 21 CFR § 803.3; or

c.

Include the following complications, which may be ongoing:
i. Pain (pelvic, vaginal, groin/thigh, dyspareunia) (acute or chronic);
ii. Foreign body reaction (acute or chronic);
iii. Erosion into organs; exposure/extrusion into vagina;
iv. Dyspareunia;
v. Scarring/scar contracture
vi. Mesh contracture;
vii.

Tissue contracture;

2 Hawaii is being represented in this matter by its Office of Consumer Protection, an agency which is not part of the
state Attorney General’s Office, but which is statutorily authorized to undertake consumer protection functions,
including legal representation o f the State of Hawaii. For simplicity, the entire group will be referred to as the
“Attorneys General,” and such designation, as it includes Hawaii, refers to the Executive Director of the State of
Hawaii Office of Consumer Protection.
3 With regard to Utah, the Utah Division of Consumer Protection is charged with administering and enforcing the
Consumer Sales Practices Act, the statute relevant to this Judgment. References to the “States,” “Parties,” or
“Attorneys General,” with respect to Utah, refers to the Utah Division of Consumer Protection.
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viii. Fistula formation (acute or chronic);
ix. Inflammation (acute or chronic);
x. Vaginal shortening or stenosis, which may result in dyspareunia
and/or sexual dysfunction;
xi. Pain with intercourse that may not resolve;
xii. Exposed mesh may cause pain or discomfort to the patient’s partner
during intercourse;
xiii. Infection;
xiv. Sexual dysfunction; including the inability to have intercourse;
xv. De novo detrusor instability;
xvi. Voiding dysfunction (incontinence, temporary or permanent lower
urinary tract obstruction, difficulty urinating, pain with urination,
overactive bladder);
xvii. Bruising, bleeding (vaginal, hematoma formation);
xviii. Abscess;
xix. Dehiscence o f vaginal incision;
xx. Perforation or laceration o f vessels, nerves, bladder, urethra, or bowel
may occur during placement; and
xxi. Failure to resolve a patient’s stress urinary incontinence
In addition, because BSC Surgical Mesh is a permanent implant, Significant Complications must
acknowledge that:
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i.

The occurrence of one or more o f these complications may require treatment
or surgical intervention. In some instances, the complication may persist as
a permanent condition after the surgical intervention or other treatment;

ii.

Removal of mesh or correction o f mesh-related complications may involve
multiple surgeries;

iii.

Complete removal o f mesh may not be possible and additional surgeries
may not always fully correct the complications.

2.11

“Inherent Mesh Complications” shall include significant complications associated

with the use of the mesh material that may not be eliminated with surgical technique (as opposed
to non-mesh surgery).
2.12

“Signatory Attorney General” means the Attorney General o f Maine, or his

authorized designee, who has agreed to this Judgment.
2.13

“Sponsor” is the organization or person who initiates a study and who has authority

and control over a study relating to BSC Surgical Mesh.
2.14

“Support” shall mean financial or product support, or as otherwise defined as

support in a contractual agreement with an HCP or consultant relating to BSC Surgical Mesh.
2.15

“State Consumer Protection Laws” means the consumer protection laws cited in

Footnote 4 under which the Attorneys General have conducted the investigation.4

4 ALABAMA - Alabama Deceptive Trade Practices Act § 8-19-1 et seq. (2002); ALASKA - Alaska Unfair Trade
Practices and Consumer Protection Act AS 45.50.471 - 45.50.561; ARIZONA - Consumer Fraud Act, A.R.S. §441521 et seq.; ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, et seq.;
CALIFORNIA - Bus. & Prof Code §§ 17200 et seq. and 17500 et seq.; COLORADO - Colorado Consumer Protection
Act, Colo, Rev. Stat. § 6-1-101 et seq.; CONNECTICUT - Connecticut Unfair Trade Practices Act, Conn. Gen Stat.
§§ 42-110a through 42-1 lOq; DELAWARE - Delaware Consumer Fraud Act, Del. CODE ANN. tit. 6, §§ 2511 to
2527; DISTRICT OF COLUMBIA, District of Columbia Consumer Protection Procedures Act, D.C. Code §§283901 et seq.; FLORIDA - Florida Deceptive and Unfair Trade Practices Act, Part II, Chapter 501, Florida Statutes,
501.201 et. seq.; GEORGIA - Fair Business Practices Act, O.C.G.A. Sections 10-1-390 etseq.; HAWAII - Uniform
Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt. 481A and Haw. Rev. Stat. Chpt. 480; IDAHO - Idaho Consumer
Protection Act, Idaho Code § 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815
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2.16

“BSC Surgical Mesh” means any medical device (as the term “device” is defined

in 21 U.S.C. § 321(h)) that contains synthetic polypropylene mesh intended to be implanted in the
pelvic floor to treat stress urinary incontinence (“SUI”) and/or pelvic organ prolapse (“POP”)
manufactured and sold by BSC in the United States.
2.17

“Valid Scientific Evidence” means evidence from well-controlled investigations,

partially controlled studies, studies and objective trials without matched controls, welldocumented case histories conducted by qualified experts, and reports o f significant human
experience with a marketed device, from which it can fairly and responsibly be concluded by
qualified experts that there is reasonable assurance of the safety and effectiveness of a device under
its conditions of use.
2.18

Any reference to a “written document” means a physical paper copy o f the

document, electronic version of the document, or electronic access to such document.

ILCS 505/2 et seq.; INDIANA - Deceptive Consumer Sales Act, Ind. Code §§ 24-5-0.5-0.1 to 24-5-0.5-12; IOWA Iowa Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Kansas Consumer Protection Act, K.S.A. 50-623
et seq.; KENTUCKY - Kentucky Consumer Protection Act, KRS Ch. 367.110, et seq.; LOUISIANA - Unfair TradePractices and Consumer Protection Law,LSA-R.S. 51:1401, et seq.; MAINE - Unfair Trade Practices Act, 5 M.R.S.A.
§§ 205-A through 214; MARYLAND - Maryland Consumer Protection Act, Md. Code Ann., Com. Law §§ 13-101 et
seq.; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4; MICHIGAN - Michigan Consumer Protection Act,
MCL § 445.901 et seq.; MINNESOTA - Minn. Stat. §§325D.44, 325F.69; MISSISSIPPI - Mississippi Consumer
Protection Act, Miss. Code Ann.§ 75-24-1, et seq.; MISSOURI - Missouri Merchandising Practices Act, Mo. Rev.
Stat. §§ 407.010 et seq.; MONTANA - Montana Consumer Protection Act §§ 30-14-101 et seq.; NEBRASKA Consumer Protection Act, Neb. Rev. Stat. §§ 59-1601 et seq. and Uniform Deceptive Trade Practices Act, Neb. Rev.
Stat. §§ 87",301 et seq.; NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.; NEW
HAMPSHIRE - NH RSA §358-A et seq; NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq.;
NEW MEXICO - NMSA 1978, § 57-12-1 et seq.; NEW YORK - General Business Law Art. 22-A, §§ 349-50, and
Executive Law § 63(12); NORTH CAROLINA - North Carolina Unfair and Deceptive Trade Practices Act, N.C.G.S.
75-1.1, et seq.; NORTH DAKOTA - Unlawful Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.;
O H IO -O h io Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma Consumer Protection
Act 15 O.S. §§ 751 et seq.; PENNS YLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law,
73 P.S. 201-1 et seq.; RHODE ISLAND - Deceptive Trade Practices Act, Rhode Island Gen. Laws § 6-13.1-1, et seq.;
SOUTH CAROLINA - South Carolina Unfair Trade Practices Act, S.C. Code Ann. § 39-5-10 et seq.; SOUTH
DAKOTA - South Dakota Deceptive Trade Practices and Consumer Protection, SDCL ch. 37-24; TENNESSEE Tennessee Consumer Protection Act, Term. Code Ann. 47-18-101 et seq.; TEXAS - Texas Deceptive Trade PracticesConsumer Protection Act, Tex. Bus. And Com. Code 17.41, et seq.; UTAH - Consumer Sales Practices Act, Utah
Code Ann. §§ 13-11 -1 et seq.; VERMONT - Vermont Consumer Protection Act, 9 V.S.A. § 2451, et seq.; VIRGINIAVirginia Consumer Protection Act, Va Code Ann. §59.1-196 et seq.; WASHINGTON - Unfair Business
Practices/Consumer Protection Act, RCW §§ 19.86 et seq.; and WISCONSIN - Wis. Stat. § 100.18 (Fraudulent
Representations).
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III.

COMPLIANCE PROVISIONS

A.

General Provisions

3.1

Sections 3.3 through 3.26 shall be effective for six years following the effective

date of this Judgment. Section 3.2 is not time restricted.
3.2

BSC shall not violate Section 207 o f the UTPA in Marketing Materials or when

promoting BSC Surgical Mesh,
B.

M arketing and Promotional Activities

3.3

BSC shall include all Significant Complications and all inherent Mesh

Complications in its Marketing Materials either by including a list o f such complications or a
reference to the applicable DFU if the inclusion of a list is not reasonably practicable given the
length of the Marketing Material and the media used, such as in reminder ads. Provided, however,
that in all instances where the Marketing Material purports to address the subject o f complications,
BSC shall include all Significant Complications and all Inherent Mesh Complications.
Additionally, in all Marketing Materials that are intended to reach consumers other than or in
addition to HCPs and that address the subject o f complications, BSC shall include descriptions of
the Significant Complications and Inherent Mesh Complications in terms reasonably
understandable to a consumer.
3.4

B SC shall not, in any Marketing Materials, state or in any way represent that any

Inherent Mesh Complications are a risk common to any pelvic floor or other surgery not involving
the use of surgical mesh or other graft material.
3.5

B SC shall not, in any Marketing Materials, state or in any way represent that

Inherent Mesh Complications can be eliminated with surgical experience or technique alone,
3.6

B SC shall not, in any Marketing Materials, state or in any way represent that BSC

Surgical M esh does not cause a foreign body reaction, including a chronic foreign body reaction.
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3.7

BSC shall not, in any Marketing Materials, state or in any way represent that BSC

Surgical M esh remains soft, supple, or pliable, or that it continues to have bi-directional elasticity
after the BSC Surgical M esh is implanted inside the body.
3.8

BSC shall not, in any Marketing Materials, state or in any way represent that BSC

Surgical M esh does not potentiate infection or does not increase the likelihood o f infection.
3.9

BSC shall not, in any Marketing Materials, state or in any way represent that BSC

Surgical Mesh is superior to traditional repair unless such representations and claims are supported
by Valid Scientific Evidence.
3.10

BSC shall not represent that BSC Surgical Mesh is “FDA approved” or that it has

undergone the FD A ’s pre-market approval process, including the requirement for clinical trials,
unless such is the case.
3.11

In any training provided by, or on behalf of, BSC to any HCPs regarding proper

procedures for insertion and implantation o f BSC Surgical Mesh, BSC shall ensure that such
training informs the HCP about Significant Complications and Inherent Mesh Complications.
3.12

BSC shall not, in any Marketing Materials, misrepresent the complexity o f BSC

Surgical M esh implantation procedure or the level o f surgical skill and/or experience necessary to
perform such a procedure safely.
C.

Disclosures to Health Care Providers

3.13

To the extent not prohibited by federal law, BSC shall include all Significant

Complications and all Inherent Mesh Complications in the DFUs for BSC Surgical Mesh products.
3.14

BSC shall inform purchasers o f BSC Surgical Mesh products within the last 24

months o f FDA Safety Alerts, Product Advisories, Recalls, and Public Health Notices directly
relating and applicable to the safety and efficacy o f BSC Surgical M esh as soon as practicable. If
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BSC obtains, receives, or is aware of any new risk information that necessitates a more immediate
disclosure for public health and safety purposes, BSC shall notify said purchasers o f this
information through other means, such as notices or letters, as appropriate given the nature o f the
new information.
3.15

W ith respect to BSC Surgical Mesh products, BSC shall comply with all FDA

regulations regarding: (1) monitoring device usage and prompt revision o f the warnings and
precautions section o f DFUs based on use experience; (2) reporting adverse events; and (3)
collection and dissemination of information pertaining to product safety.
D.
3.16

Conflicts of Interest
In all contracts for consulting services regarding Surgical Mesh between BSC and

any HCP or other consultant, including contracts for speaking engagements or presentations
relating to BSC Surgical Mesh, BSC shall include a Support disclosure provision under which the
HCP or other consultant agrees that he or she shall, in terms and in a manner so as to be clearly
noticed and understood by the audience, disclose in any public presentation or submission for
publication relating to the contracted-for activities, B SC ’s Support o f the contracted-for activities
(including

all

information

required

by

any

publication’s

conflict

disclosure

requirements). Nothing in this provision is intended to change any requirement in a BSC contract
that its prior written consent is required before any HCP or other consultant can present or publish
in relation to BSC’s contracted-for activities.
3.17

In all contracts for BSC-Sponsored studies related to BSC Surgical Mesh, BSC

shall require institutions and investigators to properly acknowledge BSC in all publications or
presentations resulting from the performance o f the Study.
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3.18

In all contracts for investigator-initiated studies related to BSC Surgical Mesh in

which BSC has provided Support, BSC shall require the investigator (if a party to the agreement)
and institution to comply with ethical standards concerning publications and authorship in the
Recommendations for the Conduct, Reporting, Editing, and Publication o f Scholarly Work in
Medical Journals established by the International Committee o f Medical Journal Editors. BSC
shall further require that the institution and investigator, if a party to the agreement, properly
acknowledge B SC ’s Support of the Study in publications.
E.

Clinical Research

3.19

BSC shall present clinical information regarding BSC Surgical Mesh in a truthful,

non-misleading manner and with a balanced presentation of risks in relation to benefits.
3.20

BSC shall not, when citing to any clinical study, clinical data, or preclinical data

regarding Surgical Mesh, misrepresent the result or scope of the cited information.
3.21

BSC shall register all BSC-Sponsored studies regarding its BSC Surgical Mesh

with ClinicalTrials.gov as required by 42 CFR Part 11.
3.22

BSC shall, when submitting a study or clinical data regarding BSC Surgical Mesh

for publication, disclose BSC’s role as a Sponsor and any potential conflict of interest with BSC
of which BSC is aware for any author consistent with the disclosure requirements for International
Committee of M edical Journal Editors (“ICMJE”).
3.23

In relation to BSC Surgical Mesh, BSC shall not, in Marketing Materials, use, rely

on, or cite to any clinical study, clinical data or preclinical data where it had control or possession
of underlying scientific materials, documents, or raw data on or after November 15,2012, but does
not retain the same for the three-year period following the last date such Marketing Materials are
distributed by BSC. This prohibition will not apply if BSC has not retained such underlying
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scientific materials, documents, or raw data if (1) it was not permitted to retain the underlying
scientific materials, documents, or raw data; or (2) the study/data was published in a peer-reviewed
journal or has otherwise entered the public domain.
3.24

In relation to BSC Surgical Mesh, BSC shall not, in Marketing Materials, use, rely

on, or cite to any clinical study, clinical data, preclinical data, research, or article, (1) for which
BSC has not complied with the disclosure requirements in Section 3.22, unless BSC provides the
disclosure detailed in Section 3.22 in the Marketing Material that uses, relies on, or cites such
clinical study, clinical data, preclinical data, research, or article; (2) Sponsored by BSC for which
the institution or investigator has not complied with the disclosure requirements set forth in Section
3.17, unless BSC provides the disclosure detailed in Section 3.17 in the Marketing Material that
uses, relies on, or cites such clinical study, clinical data, preclinical data, research, or article; or (3)
Supported by BSC for which any author/consultant/investigator has not complied with the
disclosure requirements set forth in Sections 3.16 or 3.18, unless BSC discloses the conflict,
consistent with the conflict of interest disclosure requirements o f the ICMJE, in the Marketing
Material that uses, relies on, or cites such clinical study, clinical data, preclinical data, research, or
article.
F.

Policies and Training

3.25

BSC shall maintain policies requiring that its independent contractors, agents, and

employees who sell, market, or promote BSC Surgical Mesh or otherwise communicate with
HCPs, nurses, physician’s assistants, and other medical professionals, regarding BSC Surgical
Mesh, are adequately trained to report patient complaints and/or adverse events to BSC.
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3.26

BSC shall ensure that its responses to requests for medical information regarding

BSC Surgical M esh and complications associated with BSC Surgical M esh are accurate and
truthful.
G.

M onitoring and Compliance

3.27

BSC shall be responsible for monitoring and compliance with the provisions o f this

Judgment,
IV.
4.1

MONETARY RELIEF

No Later than 30 days after the Effective Date o f this Judgment, BSC shall pay a total

amount o f One Hundred Eighty-Eight Million, Six Hundred Fifty-Five Thousand, Sixty-Seven
Dollars ($188,655,067).5 This amount shall be divided and paid by BSC to each Signatory
Attorney General o f the Multistate Working Group in an amount to be designated by and in the
sole discretion o f the Multistate Executive Committee. The Parties acknowledge that no portion
of the payment is a fine or penalty. The states may use the payment in any o f the following ways:
(1) to pay for attorney’s fees and other costs o f investigation and litigation; (2) to place in, or apply
to, consumer protection enforcement, including future consumer protection enforcement,
consumer education, litigation, or local consumer aid or revolving funds; (3) to defray the costs of
the inquiry leading to this Judgment; and/or (4) for any lawful purpose, at the sole discretion of
each Signatory Attorney General.
V.
5.1

ENFORCEMENT

For the purposes o f resolving disputes with respect to compliance with this

Judgment, should any of the Signatory Attorneys General have a reasonable basis to believe that
BSC has engaged in a practice that violates a provision o f this Judgment subsequent to the

5 The payment to the Signatory Attorney General under this Section shall be $1,316,102.
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Effective Date, then such Attorney General shall notify BSC in writing o f the specific objection,
identify with particularity the provision o f this Judgment that the practice appears to violate, and
give BSC thirty (30) days to respond to the notification; provided, however, that a Signatory
Attorney General may take any action if the Signatory Attorney General believes that, because of
the specific practice, a threat to the health or safety o f the public requires immediate action. Upon
receipt of written notice, BSC shall provide a good-faith written response to the Signatory Attorney
GeneraPs notification, containing either a statement explaining why BSC believes it is in
compliance with the Judgment, or a detailed explanation of how the alleged violation occurred and
a statement explaining how BSC intends to remedy the alleged violation. The Signatory Attorney
General may agree, in writing, to provide BSC with additional time beyond the thirty (30) days to
respond to a notice. Nothing in this section shall be interpreted to limit the Signatory Attorney
GeneraPs Civil Investigative Demand (“CID”) or investigative subpoena authority, to the extent
such authority exists under applicable law. BSC reserves all o f its rights in responding to a CID
or investigative subpoena issued pursuant to such authority.
5.2

Upon giving BSC thirty (30) days to respond to the notification described above,

the Signatory Attorney General shall also be permitted reasonable access to inspect and copy
relevant, non-privileged, non-work product records and documents in the possession, custody, or
control of BSC that relate to BSC’s compliance with each provision o f this Judgment pursuant to
the Signatory Attorney GeneraPs CID or investigative subpoena authority. If the Signatory
Attorney General makes or requests copies o f any documents during the course o f that inspection,
the Signatory Attorney General will provide a list o f those documents to BSC.
5.3

The State may assert any claim that BSC has violated this Judgment in a separate

civil action to enforce compliance with this Judgment, or may seek any other relief afforded by
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law for violations o f the Judgment, but only after providing BSC an opportunity to respond to the
notification described in Section 5,1 above; provided, however, that a Signatory Attorney General
may take any action if the Signatory Attorney General believes that, because o f the specific
practice, a threat to the health or safety o f the public requires immediate action.
V I.
6.1

RELEA SE

Released Claims. By its execution o f this Judgment, the State of Maine releases

and forever discharges BSC and its past and present officers, directors, shareholders, employees,
representatives, agents, affiliates, parents, subsidiaries, predecessors, attorneys, assigns and
successors (collectively, the “Releasees”) Rom the following: all civil causes o f action, claims,
damages, restitution, fines, costs, attorney’s fees, remedies or penalties that the Maine Attorney
General has asserted or could have asserted against the Released Parties under the State Consumer
Protection Statutes resulting Rom the Covered Conduct up to and including the Effective Date
except as set forth in Section 6.2 below.
6.2

Claims N ot Covered. Notwithstanding any term o f this Judgment, specifically

reserved and excluded from the Released Claims in Section 6.1 as to any entity or person, including
Releasees, are any and all o f the following, to which BSC expressly reserves each and every
available defense:
(a)

Any criminal liability that any person or entity, including Releasees, has or may
have to the State of Maine;

(b)

Any civil or administrative liability that any person or entity, including Releasees,
has or may have to the State o f Maine not expressly covered by the release in
Section 6.1, including, but not limited to, any and all o f the following claims:
i.

State or federal antitrust violations;
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ii

Claims involving “best price,” “average wholesale price,” “wholesale
acquisition cost,” or any reporting practices;

iii.

M edicaid claims, including, but not limited to, federal Medicaid device
rebate statute violations, Medicaid fraud or abuse (whether common law,
statutory or otherwise), and/or kickback violations related to any state’s
Medicaid program;

(c)

iv.

State false claims violations; and

v.

Claims to enforce the terms and conditions o f this Judgment.

Actions of, or on behalf of, state program payors o f the State o f Maine arising from
the purchase o f BSC Surgical Mesh.

(d)

Any claims individual consumers have or may have under any o f the above-cited
State Consumer Protection Laws against any person or entity, including the
Releasees.

6.3

Nothing contained in this Judgment shall relieve BSC of the obligations it maintains

under any other Judgment or agreement relating to any of BSC’s products.
VIL
7.1

ADDITIONAL PROVISIONS

If, subsequent to the Effective Date o f this Judgment, the federal government, the

FDA, or any state or state agency enacts legislation, regulation, policy or guidance with respect to
matters governed by this Judgment that creates a conflict with any provision o f the Judgment, and
such conflict makes it impossible for BSC to comply with both the newly enacted legislation,
regulation, policy, or guidance and the provision o f the Judgment that BSC claims is the subject
of the conflict, BSC shall provide the Attorney General with notice o f the impossible conflict,
which shall include an explanation as to how the newly enacted legislation, regulations, policies
or guidance creates a conflict and makes it impossible for BSC to comply with the subject
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provision o f the Judgment. The Attorney General shall have thirty (30) days from receipt o f the
notice to either notify BSC that it agrees to a modification o f the Judgment to address the conflict
BSC raised, or notify BSC that the Attorney General does not agree that a conflict exists that makes
it impossible for BSC to comply with both the legislation, regulation, policy, or guidance and the
subject provision o f the Judgment, in which case BSC, subject to an Order to the contrary from
this Court, must comply with both the newly enacted legislation, regulations, policies or guidance
and the provision o f the Judgment.
7.2

Nothing in this Judgment shall be construed to authorize or require any action by

BSC in violation o f applicable federal, state, or other laws.
7.3

M odification: The Judgment may be modified by a stipulation o f the Parties, once

it is approved by and becomes a judgment o f the Court, or by court proceedings resulting in a
modified Judgment o f the Court.
7.4

BSC shall not cause or encourage third parties, nor knowingly permit third parties

acting on its behalf, to engage in practices from which BSC is prohibited by this Judgment.
7.5

The Attorney General may, at his sole discretion, agree in writing to provide BSC

with additional time to perform any act required by this Judgment.
7.6

The acceptance of this Judgment by the State o f Maine shall not be deemed

approval by the State o f Maine of any o f BSC’s advertising or business practices. Further, neither
BSC nor anyone acting on its behalf shall state or imply, or cause to be stated or implied, that the
State of Maine or any o f its governmental units has approved, sanctioned or authorized any
practice, act, advertisement, or conduct o f BSC,
7.7

Any failure by any party to this Judgment to insist upon the strict performance by

any other party o f any of the provisions o f this Judgment shall not be deemed a waiver of any of
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the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance o f any and all o f the provisions o f this Judgment.
7.8

Entire Agreement: This Judgment represents the full and complete terms o f the

settlement entered into by the Parties. In any action undertaken by the Parties, no prior version of
this Judgment and no prior version o f any of its terms that were not entered by the Court in this
Judgment, may be introduced for any purpose whatsoever.
7.9

Jurisdiction: This Court retains jurisdiction over this Judgment and the Parties for

the purpose of enforcing and modifying this Judgment and granting such additional relief as may
be necessary and appropriate.
7.10

N otice: All Notices under this Judgment shall be provided to the following via

email and Overnight Mail:
BSC:
Eileen M. Hunter
Vice President
Head o f Global Litigation
Head of Legal Operations
4100 Hamline Ave N,
St. Paul, M N 55112
eileen.hunter@bsci.com
CC: Boston Scientific Corporation's attorneys:
Joseph Rebein
Shook, Hardy & Bacon, L.L.P.
2555 Grand Blvd.
Kansas City, MO 64018
jrebein@ shb. com
Amy R. Fiterman
Faegre Drinker Biddle & Reath LLP
2200 Wells Fargo Center
90 S. Seventh Street
M inneapolis, MN 55402
amy.fiterman@faegredrinlcer.com
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Signatory Attorney General:
Linda J. Conti, Chief
Consumer Protection Division
Office of the Maine Attorney General
Burton Cross Office Building
111 Sewall Street, 6th Floor
Augusta, M E 04330
Linda .conti@maine, gov
7.10

To the extent that any provision o f this Judgment obligates BSC to change any

policy or procedure and to the extent not already accomplished, BSC shall implement any such
policy or procedure as soon as reasonably practicable, but no later than 120 days after the Effective
Date of this Judgment.
BSC will revise its current BSC Surgical Mesh DFUs (the “Current DFUs”) to comply
with the terms o f this Judgment, including by, among other things, listing all Significant
Complications and Inherent Mesh Complications and ensuring the revised DFU (the “Updated
DFU”) conforms with the provisions o f Section III.B, as soon as reasonably practicable, but no
later than 18 months from the Effective Date of this Judgment.
Once there is an Updated DFU available for a product, BSC shall cease packaging that
product with the Current DFU.
BSC will make reasonable efforts to deliver Updated DFUs to all HCPs known to implant
BSC Surgical M esh as soon as reasonably practicable after Updated DFUs are available, but no
later than 18 months after the Effective Date of this Judgment.
This Judgment does not require BSC to collect or remove pre-existing materials from the
public domain. However, BSC shall remove materials available that are inconsistent with this
Judgment over which it has control such as materials posted on websites controlled by BSC.
IT IS SO ORDERED.
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4 ~ Jl2

Date:

Justice, Maine Superior Court

Dated:

z .^

ZOZt

MAINE ATTORNEY GENERAL
AARON M. FREY

Linda J. C opi, Maine Bar No. 363,
Linda.conti@maine.gov
'
Carolyn A. Silsby, Maine Bar No. 3030
Carolvn.siisbv@mame.gov
Assistant Attorneys General
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207) 626-8800
ATTORNEYS FOR PLAINTIFF

For Defendant Boston Scientific Corporation

By:

y jJ d iZ T ________________
Eileen M, Hunter
Vice President
Head o f Global Litigation
Head of Legal Operations

,
SDate

Local Counsel for Boston Scientific Corporation

By:___________________________________
Jesse Weisshaar
Maine Bar No, 005570
Shook, Hardy & Bacon, L.L.P.
1800 IC. Street NW, Suite 1000
Washington, D.C. 20006
jweisshaar@shb.com

____
Date
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H ill

Date:
Justice, Maine Superior Court

Dated:

MAINE ATTORNEY GENERAL
AARON M. FREY

Linda J. Conti, Maine Bar No. 3638
Linda.conti@maine.gov
Carolyn A. Silsby, Maine Bar No. 3030
Carolvn.silsbv@maine.gov
Assistant Attorneys General
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207) 626-8800
ATTORNEYS FOR PLAINTIFF

For Defendant Boston Scientific Corporation

Eileen M. Hunter
Vice President
Head of Global Litigation
Head of Legal Operations

Date

Local Counsel for Boston Scientific Corporation

Jesse W eisshaar
Maine Bar No. 005570
Shook, Hardy & Bacon, L.L.P.
1800 K. Street NW, Suite 1000
Washington, D.C. 20006
jweisshaar@shb.com
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